Olanzapine for Chemotherapy-Induced Vomiting in Children
This study is testing if adding olanzapine to standard anti-nausea medications can better control vomiting caused by chemotherapy in children. Many children receiving strong chemotherapy (highly emetogenic chemotherapy, HEC) still experience vomiting despite current treatments. Olanzapine has helped adults with similar issues and has been used safely in children for other conditions. This trial will compare olanzapine to a placebo (an inactive pill that looks like olanzapine) in about 200 children aged 30 months to 18 years who are receiving HEC. The main goal is to see if olanzapine improves vomiting control during the first 8 days of chemotherapy. The study's current status is unclear.
- Study design
- This is an interventional study involving about 200 participants. It compares olanzapine to a placebo (an inactive pill).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome measures vomiting control for up to 8 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
At a glance
Conditions
Where it's being run
9 sites across 9 statesStudy leadership
- Lee Dupuis, RPh, PhD · PRINCIPAL_INVESTIGATOR · The Hospital for Sick Children
- Muhammad Ali, MD · PRINCIPAL_INVESTIGATOR · The Hospital for Sick Children
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Rate of CIV control during the acute phaseup to 8 days
Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase
- Rate of CIV control during the acute phaseup to 8 days
Partial control is defined as no more than two vomits or retches during any 24-hr period